Asymchem, a global contract development and manufacturing organisation (CDMO), has appointed Franck Mevellec as Senior Director of business development.
Franck brings more than 20 years of experience in the pharmaceutical industry, working across various aspects of drug development — from R&D to sales.
Mevellec boasts a proven track record of success, having held key positions at industry leaders like Bayer Healthcare (R&D), Teva Pharmaceuticals (portfolio director), Minakem (BD director) and most recently, Seqens (global head of sales).
He joins Asymchem with a focus on expanding the company’s footprint across Europe.
“Franck’s extensive experience and deep understanding of the European pharmaceutical market make him a valuable asset to our team,” said SVP of business development at Asymchem, Jon Bryce. His leadership and entrepreneurial spirit will be instrumental in driving our growth and strengthening our presence in this region.”
In his new role, Franck will leverage his expertise to develop new business opportunities for Asymchem, focusing on a wide range of services including flow chemistry, oligo and peptides, drug product development and biologics.
